How long do people stay on GLP-1s?

Two answers exist — what medicine recommends and what people actually do — and the gap between them is where most disappointment lives. The clinical model: a loss phase of roughly 12–18 months (titration plus the long slide to plateau), then a maintenance phase measured in years — possibly indefinitely — because stopping reverses the biology. Two-year trials (STEP 5, SURMOUNT-4 continuation arms) show sustained results and declining side effects with continued use; long-term safety data is reassuring. Maintenance increasingly means less drug — lower doses or stretched intervals (the microdose conversation) — so “staying on” needn’t mean full-dose forever, in either side effects or dollars. The real-world pattern: pharmacy-claims analyses have found large shares of weight-loss GLP-1 users discontinuing within a year. The drivers, in rough order: cost and coverage changes (the cash-pay math matters at multi-year horizons), side effects that better titration management might have salvaged, the shortage-era supply chaos (now resolved), and the understandable but biology-blind instinct that goal weight = finished. The mental-model correction that helps most: ask “how long do people stay on blood-pressure medication?” Nobody expects lisinopril to cure hypertension so you can stop; weight regulation is proving similarly chronic. The useful planning questions are budget-shaped (can I sustain ≈$200–500/month for years if needed → savings strategies) and identity-shaped (build the habit infrastructure during the loss phase, so whatever dose you land on long-term has the most help). And if you do want off: there’s a smarter way to attempt it than just stopping.